This dependence has been demonstrated by treating glioma, leukemia, ovarian, and breast cell lines with suicide inactivators of MGMT, O6-benzylguanine (O6-BG) [33] or 6-[(4-bromo-2-thienyl)methoxy]-9H-purin-2-amine (PaTrin-2) [34,35,36]; MGMT inhibition increased sensitivity to TMZ treatment. The gene discussed is MGMT; the disease is central nervous system cancer.